title: A randomized, placebo-controlled proof-of-concept trial of adjunctive topiramate for alcohol use disorders in bipolar disorder.
abstract: OBJECTIVE
  Topiramate is effective for alcohol use disorders (AUDs) among non-psychiatric patients. We examined topiramate for treating comorbid AUDs in bipolar disorder (BD).
  
  
  METHODS
  Twelve participants were randomized to topiramate or placebo for 12 weeks.
  
  
  RESULTS
  The topiramate group, with two out of five participants (40%) completing treatment, experienced less improvement in drinking patterns than the placebo group, with five out of seven participants (71%) completing treatment.
  
  
  CONCLUSIONS
  Topiramate did not improve drinking behavior and was not well-tolerated. This study failed to recruit adequately. Problems surrounding high attrition, a small study sample, and missing data preclude interpretation of study findings.
  
  
  CONCLUSIONS
  This is the first randomized, placebo-controlled trial of topiramate for AUDs in BD.
authors.affiliation: Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts.|Harvard Medical School, Boston, Massachusetts.
authors.forename: Louisa G
authors.initials: LG
authors.lastname: Sylvia
authors.affiliation: Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts.
authors.forename: Alexandra K
authors.initials: AK
authors.lastname: Gold
authors.affiliation: Department of Psychology, Temple University, Philadelphia, Pennsylvania.
authors.forename: Jonathan P
authors.initials: JP
authors.lastname: Stange
authors.affiliation: Department of Psychology, University of California, Berkeley, California.
authors.forename: Andrew D
authors.initials: AD
authors.lastname: Peckham
authors.affiliation: Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts.|Harvard Medical School, Boston, Massachusetts.
authors.forename: Thilo
authors.initials: T
authors.lastname: Deckersbach
authors.affiliation: Bipolar Disorders Research Center, University Hospitals Case Medical Center, Case Western Reserve University, Cleveland, Ohio.
authors.forename: Joseph R
authors.initials: JR
authors.lastname: Calabrese
authors.affiliation: Harvard Medical School, Boston, Massachusetts.|Division of Alcohol and Drug Abuse, McLean Hospital, Belmont, Massachusetts.
authors.forename: Roger D
authors.initials: RD
authors.lastname: Weiss
authors.affiliation: Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts.|Harvard Medical School, Boston, Massachusetts.
authors.forename: Roy H
authors.initials: RH
authors.lastname: Perlis
authors.affiliation: Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts.|Harvard Medical School, Boston, Massachusetts.
authors.forename: Andrew A
authors.initials: AA
authors.lastname: Nierenberg
authors.affiliation: Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, California.
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Ostacher
mesh_terms: D000428:Alcohol Drinking / Q000188:drug therapy; D019973:Alcohol-Related Disorders / Q000150:complications* / Q000188:drug therapy*; D001714:Bipolar Disorder / Q000150:complications*; D017831:Diagnosis, Dual (Psychiatry); D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D005632:Fructose / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D018696:Neuroprotective Agents / Q000627:therapeutic use; D000077236:Topiramate; D016896:Treatment Outcome
chemical_list: D018696:Neuroprotective Agents; D000077236:Topiramate; D005632:Fructose